Status: Recruiting
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Participants needed: 380
Trial details
Age: 18-100Biological sex: AllType: ObservationalSponsor: Novartis PharmaceuticalsUpdated: Oct 7, 2026Locations: 69
Eligibility criteria
Written informed consent must be obtained before participation in the study/prio... [+4]
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lac... [+8]